| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Faron Pharmaceuticals secures US rights to patent related to Traumakine
StockMarketWire.com
|
Clinical stage biopharmaceutical company Faron Pharmaceuticals said it had signed a sub-license agreement for the rights to U.S. patent related to patent related to Traumakine.
Traumakine is intended for to treat capillary leak and systemic inflammatory response syndromes including acute respiratory distress syndrome (ARDS) in the U.S.
Patent US9,376,478 currently extends to 2033.
At 8:47am: (LON:FARN) Faron Pharmaceuticals share price was 0p at 275p
Story provided by StockMarketWire.com
|
|
|
|
|
|
